Tandem Diabetes Care, Inc (NASDAQ:TNDM) Poised For Near-Term Upside As Momentum Rebuilds

Tandem shows stretched profitability but improving technical momentum and tangible cash buffers that support a measured rebound over the immediate weeks ahead.

Recent News

On August 6, 2025 the company released its second-quarter 2025 financial results and updated full-year 2025 guidance, narrowing full-year sales guidance to approximately $1.0 billion and revising non-GAAP adjustments for acquired in‑process R&D; the company also updated its non-GAAP presentation to exclude an IPR&D adjustment beginning in Q2.

Technical Analysis

Directional indicators show a low-strength market: ADX at 14.1 signals no established trend, but the directional movement lines favor the upside — DI+ registered a dip-and-reversal (bullish) while DI‑ decreased (bullish), implying that short-term directional pressure points toward recovery relative to the stock’s fair-valued baseline.

MACD sits at -$0.14 while the signal line sits at -$0.32; MACD increased and crossed above its signal line, a bullish momentum confirmation that supports the prospect of a short-term push higher from current levels.

MRO registers -11.82, a negative reading that indicates the market price sits below the model target and therefore carries measurable upside potential; the magnitude suggests moderate upward pressure into the near term.

RSI at 42.54 and rising shows building buying interest without overextension, which aligns with a recovery scenario that retains room to move higher before reaching neutral territory.

Price structure supports a contained rebound: the close at $12.77 sits above the 20‑day average $12.56 and the 12‑day EMA showed a dip-and-reversal, while the stock remains below the 50‑day average $13.17 and well below the 200‑day average $22.20. Bollinger band widths remain narrow with the 1x upper band at $12.92 and lower at $12.20, and SuperTrend lower support at $11.30 provides a nearby structural floor. Volume on the latest session, ~1.54M, tracked below the 10‑day average, indicating moves have lacked high conviction so far.

 


Fundamental Analysis

Profitability shows ongoing strain: EBIT at -$55,185,000 produces an EBIT margin of -22.93%, well below the industry peer mean of 18.51% and industry peer median of 17.48%. QoQ the EBIT margin declined by -55.48%, while YoY the EBIT margin improved by 82.05% versus prior-year levels, reflecting wide quarter-to-quarter swings in operating profitability.

Top-line and growth metrics present mixed signals. Reported total revenue equals $240,678,000. Reported revenue growth stands at 2.67% on one metric, while reported revenue growth year-over-year shows -83.08% and quarter-over-quarter change shows -115.64%; those contrasting growth indicators indicate volatile period-to-period comparisons that require careful calendar alignment when interpreting trend changes.

Cash and liquidity provide a meaningful buffer: cash and short-term investments total $315,361,000, cash ratio 1.25, current ratio 2.44 and quick ratio 1.88, supporting operations despite negative free cash flow of -$15,702,000 and operating cash flow -$9,496,000. Free cash flow growth shows a strong YoY gain per the provided metric, but free cash flow itself remains negative for the latest period.

Leverage sits elevated: total debt $449,008,000 produces a debt-to-equity ratio of 336.88% versus an industry peer mean of 62.67%, and debt-to-assets 51.27% indicates material leverage on the balance sheet. Interest expense remains small in absolute terms at $2,537,000 and cost of debt at 0.489%.

Market multiples present mixed signals. Price-to-book at 7.73 runs above the industry peer mean of 6.29 and median of 6.87, while trailing PE appears negative due to losses. EPS came in at -$0.48 versus an estimate of -$0.40, producing an EPS surprise of -20%. Forward EPS remains negative, and the enterprise multiple and forward multiples reflect the company’s loss-making status on a GAAP basis. Gross margin at 52.29% underperforms the industry peer mean of 62.20%, even as gross profit totals $125,855,000.

WMDST values the stock as fair-valued given the combination of large cash resources, above-average leverage, stretched profitability, and the mixed growth signals that showed both QoQ deterioration and YoY improvement in selected margins.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-06
NEXT REPORT DATE: 2025-10-29
CASH FLOW  Begin Period Cash Flow 53.6 M
 Operating Cash Flow -9.50 M
 Capital Expenditures -6.21 M
 Change In Working Capital 9.2 M
 Dividends Paid
 Cash Flow Delta 10.5 M
 End Period Cash Flow 64.1 M
 
INCOME STATEMENT REVENUE
 Total Revenue 240.7 M
 Forward Revenue 23.5 M
COSTS
 Cost Of Revenue 114.8 M
 Depreciation 4.4 M
 Depreciation and Amortization 4.4 M
 Research and Development 48.1 M
 Total Operating Expenses 272.5 M
PROFITABILITY
 Gross Profit 125.9 M
 EBITDA -50.82 M
 EBIT -55.19 M
 Operating Income -31.86 M
 Interest Income
 Interest Expense 2.5 M
 Net Interest Income -2.54 M
 Income Before Tax -57.72 M
 Tax Provision -5.32 M
 Tax Rate 9.22 %
 Net Income -52.40 M
 Net Income From Continuing Operations -52.40 M
EARNINGS
 EPS Estimate -0.40
 EPS Actual -0.48
 EPS Difference -0.08
 EPS Surprise -20.0 %
 Forward EPS -0.30
 
BALANCE SHEET ASSETS
 Total Assets 875.7 M
 Intangible Assets
 Net Tangible Assets 133.3 M
 Total Current Assets 614.8 M
 Cash and Short-Term Investments 315.4 M
 Cash 64.1 M
 Net Receivables 128.4 M
 Inventory 142.6 M
 Long-Term Investments 17.3 M
LIABILITIES
 Accounts Payable 55.8 M
 Short-Term Debt
 Total Current Liabilities 251.7 M
 Net Debt 245.0 M
 Total Debt 449.0 M
 Total Liabilities 742.5 M
EQUITY
 Total Equity 133.3 M
 Retained Earnings -1.23 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 1.97
 Shares Outstanding 67.531 M
 Revenue Per-Share 3.56
VALUATION
 Market Capitalization 1.0 B
 Enterprise Value 1.2 B
 Enterprise Multiple -22.901
Enterprise Multiple QoQ 65.204 %
Enterprise Multiple YoY -76.473 %
Enterprise Multiple IPRWA high: 123.29
median: 110.415
mean: 94.184
TNDM: -22.901
low: -147.649
 EV/R 4.835
CAPITAL STRUCTURE
 Asset To Equity 6.571
 Asset To Liability 1.18
 Debt To Capital 0.771
 Debt To Assets 0.513
Debt To Assets QoQ -4.136 %
Debt To Assets YoY 1085.754 %
Debt To Assets IPRWA high: 0.843
TNDM: 0.513
mean: 0.298
median: 0.289
low: 0.0
 Debt To Equity 3.369
Debt To Equity QoQ 6.072 %
Debt To Equity YoY 1843.481 %
Debt To Equity IPRWA TNDM: 3.369
high: 2.173
mean: 0.627
median: 0.579
low: -0.395
PRICE-BASED VALUATION
 Price To Book (P/B) 7.729
Price To Book QoQ -19.408 %
Price To Book YoY -33.852 %
Price To Book IPRWA high: 16.759
TNDM: 7.729
median: 6.869
mean: 6.287
low: -5.981
 Price To Earnings (P/E) -38.025
Price To Earnings QoQ 12.167 %
Price To Earnings YoY -56.295 %
Price To Earnings IPRWA high: 249.6
mean: 136.734
median: 121.658
TNDM: -38.025
low: -167.592
 PE/G Ratio 1.341
 Price To Sales (P/S) 4.28
Price To Sales QoQ -32.628 %
Price To Sales YoY -65.242 %
Price To Sales IPRWA high: 73.117
mean: 32.467
median: 24.499
TNDM: 4.28
low: 0.6
FORWARD MULTIPLES
Forward P/E -70.219
Forward PE/G 2.476
Forward P/S 43.916
EFFICIENCY OPERATIONAL
 Operating Leverage -20.344
ASSET & SALES
 Asset Turnover Ratio 0.268
Asset Turnover Ratio QoQ 7.921 %
Asset Turnover Ratio YoY 13.324 %
Asset Turnover Ratio IPRWA high: 0.412
TNDM: 0.268
median: 0.124
mean: 0.121
low: 0.008
 Receivables Turnover 1.888
Receivables Turnover Ratio QoQ -2.911 %
Receivables Turnover Ratio YoY -18.73 %
Receivables Turnover Ratio IPRWA high: 3.133
TNDM: 1.888
mean: 1.734
median: 1.672
low: 0.374
 Inventory Turnover 0.809
Inventory Turnover Ratio QoQ 1.427 %
Inventory Turnover Ratio YoY 17.031 %
Inventory Turnover Ratio IPRWA high: 2.014
TNDM: 0.809
mean: 0.648
median: 0.568
low: 0.084
 Days Sales Outstanding (DSO) 48.341
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 114.449
Cash Conversion Cycle Days QoQ -0.314 %
Cash Conversion Cycle Days YoY -19.737 %
Cash Conversion Cycle Days IPRWA high: 448.876
mean: 171.048
median: 167.784
TNDM: 114.449
low: -175.55
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.663
 CapEx To Revenue -0.026
 CapEx To Depreciation -1.421
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 442.4 M
 Net Invested Capital 442.4 M
 Invested Capital 442.4 M
 Net Tangible Assets 133.3 M
 Net Working Capital 363.1 M
LIQUIDITY
 Cash Ratio 1.253
 Current Ratio 2.443
Current Ratio QoQ 6.105 %
Current Ratio YoY -19.858 %
Current Ratio IPRWA high: 19.146
mean: 2.549
TNDM: 2.443
median: 1.718
low: 0.027
 Quick Ratio 1.876
Quick Ratio QoQ 3.529 %
Quick Ratio YoY -21.037 %
Quick Ratio IPRWA high: 12.697
mean: 1.88
TNDM: 1.876
median: 1.167
low: 0.315
COVERAGE & LEVERAGE
 Debt To EBITDA -8.836
 Cost Of Debt 0.489 %
 Interest Coverage Ratio -21.752
Interest Coverage Ratio QoQ -75.551 %
Interest Coverage Ratio YoY 39.54 %
Interest Coverage Ratio IPRWA high: 52.298
mean: 15.503
median: 11.456
TNDM: -21.752
low: -88.481
 Operating Cash Flow Ratio -0.22
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 45.477
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate -5.033 %
 Revenue Growth 2.669 %
Revenue Growth QoQ -115.643 %
Revenue Growth YoY -83.081 %
Revenue Growth IPRWA high: 26.158 %
median: 8.281 %
mean: 6.321 %
TNDM: 2.669 %
low: -39.052 %
 Earnings Growth -28.358 %
Earnings Growth QoQ -99.577 %
Earnings Growth YoY 19.101 %
Earnings Growth IPRWA high: 166.667 %
mean: 11.366 %
median: 9.851 %
TNDM: -28.358 %
low: -180.612 %
MARGINS
 Gross Margin 52.292 %
Gross Margin QoQ 3.528 %
Gross Margin YoY 2.878 %
Gross Margin IPRWA high: 91.006 %
median: 63.683 %
mean: 62.2 %
TNDM: 52.292 %
low: -7.085 %
 EBIT Margin -22.929 %
EBIT Margin QoQ -55.479 %
EBIT Margin YoY 82.048 %
EBIT Margin IPRWA high: 33.709 %
mean: 18.512 %
median: 17.478 %
TNDM: -22.929 %
low: -200.872 %
 Return On Sales (ROS) -13.237 %
Return On Sales QoQ -74.298 %
Return On Sales YoY 5.097 %
Return On Sales IPRWA high: 39.857 %
mean: 19.015 %
median: 18.374 %
TNDM: -13.237 %
low: -193.243 %
CASH FLOW
 Free Cash Flow (FCF) -15.70 M
 Free Cash Flow Yield -1.524 %
Free Cash Flow Yield QoQ -64.925 %
Free Cash Flow Yield YoY 254.419 %
Free Cash Flow Yield IPRWA high: 4.685 %
median: 0.712 %
mean: 0.678 %
TNDM: -1.524 %
low: -19.501 %
 Free Cash Growth -75.734 %
Free Cash Growth QoQ -213.103 %
Free Cash Growth YoY 1224.716 %
Free Cash Growth IPRWA high: 310.383 %
mean: 85.695 %
median: 14.619 %
TNDM: -75.734 %
low: -376.098 %
 Free Cash To Net Income 0.3
 Cash Flow Margin -22.971 %
 Cash Flow To Earnings 1.055
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) -5.829 %
Return On Assets QoQ -57.813 %
Return On Assets YoY 77.659 %
Return On Assets IPRWA high: 16.404 %
mean: 1.756 %
median: 1.686 %
TNDM: -5.829 %
low: -26.44 %
 Return On Capital Employed (ROCE) -8.843 %
 Return On Equity (ROE) -0.393
Return On Equity QoQ -53.236 %
Return On Equity YoY 198.406 %
Return On Equity IPRWA high: 0.175
median: 0.032
mean: 0.029
TNDM: -0.393
low: -0.524
 DuPont ROE -36.317 %
 Return On Invested Capital (ROIC) -11.323 %
Return On Invested Capital QoQ -21.105 %
Return On Invested Capital YoY -311.211 %
Return On Invested Capital IPRWA high: 5.672 %
median: 2.571 %
mean: 2.238 %
TNDM: -11.323 %
low: -19.888 %

Six-Week Outlook

Technical setup favors a capped recovery: bullish DI+ reversal, MACD crossing above its signal, a negative MRO indicating upside potential, and a rising RSI combine to support a move back toward the 50‑day average near $13.17. Expect price action to remain range‑bound between the nearby support at $11.30 and resistance around the 50‑day average, with upside moves likely to test the upper 1x Bollinger band near $12.92 before challenging the 50‑day. Lower-than-average volume on recent sessions suggests breakouts may require higher sustained volume to carry beyond resistance. Given elevated leverage and negative GAAP profitability, fundamental catalysts that alter guidance or cash usage could shift this outlook quickly; absent such changes, anticipate a measured technical-led rebound rather than an extended trend initiation.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) develops and commercializes advanced medical technology solutions for diabetes management. Headquartered in San Diego, California, the company delivers innovative products to the United States and international markets. Tandem’s flagship product, the t:slim X2 insulin delivery system, integrates insulin delivery with continuous glucose monitoring, offering users streamlined management of their diabetes. Additionally, the Tandem Mobi insulin pump provides automated insulin delivery, enhancing user convenience and control. Tandem also offers a range of single-use products, including insulin cartridges and infusion sets, which facilitate the connection between the insulin pump and the user’s body. The Tandem Device Updater allows users to update their pump software through a personal computer, ensuring they have access to the latest features and improvements. The company’s Tandem Source platform provides a web-based solution for visualizing diabetes therapy data, integrating information from pumps, continuous glucose monitors, and blood glucose meters. Furthermore, the Sugarmate mobile app assists users in visualizing and managing their diabetes therapy data. Tandem Diabetes Care, Inc., originally incorporated as Phluid Inc. in 2006, adopted its current name in 2008.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.